A method for using life tables to estimate lifetime risk for prostate cancer death

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 2, 2010, Pages 148-154

  Kim, Hyung L ^a   Puymon, Marvin R ^b   Qin, Maochun ^c   Guru, Khurshid ^c,d   Mohler, James L ^c,d,e  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Conseco Services LLC ^*  (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Life expectancy; Life table; Observation; Prostate cancer; Watchful waiting

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; COUNSELING; DECISION MAKING; DYING; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; LIFE TABLE; LIFESPAN; MALE; PROSTATE CANCER; SOCIAL SECURITY;

EID: 77649156342     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0011     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982;29:611-616.
3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-66.
4. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
5. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-848.
6. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
7. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938-1942.
8. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-2101.
9. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719.
10. Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008;112:69-74.
11. Mohler J, Amling, CL, Bahnson RR, et al. NCCN clinical practice guidelines in oncology: prostate cancer. Version 2, 2009. Available at: http://www.nccn.org/professionals/physician-gls/PDF/prostate. pdf. Accessed December 29, 2009.
12. Alberrsen P. Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer 2008;112:1-3.
13. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-2149.
14. Schroder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003;92(Suppl 2):1-13.
15. Andriole GL, Reding D, Hayes RB, et al. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol 2004;22:358-361.
16. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294.
17. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152:1743-1748.
18. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-878.